Lupin to present key oncology data at ESMO Congress

Lupin Limited will present Phase 1 data from its LNP3693 (STING agonist) clinical trial at the ESMO Congress in Berlin, Germany, from October 17-21, 2025. The presentation is scheduled for October 19, 2025, between 09:00 and 17:00 CEST, under Presentation Number 1553P.

LNP3693 is an investigational parenteral STING agonist. The presentation will highlight insights into its safety, pharmacokinetics, pharmacodynamics, and preliminary anti-tumor activity. This follows Lupin's earlier presentation of LNP7457, a PRMT5 inhibitor, at ASCO in June 2025, underscoring the company's proficiency in oncology drug discovery and development. All accepted abstracts will be published online via the ESMO website and in the *Annals of Oncology* on October 13, 2025, at 6:05 p.m. ET (12:05 a.m. CEST).